Cilostazol

CHEMBL799 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

369.5 g/mol

LogP

3.1

Phase

4

A phosphodiesterase 3 inhibitor that inhibits platelet aggregation and acts as a vasodilator, used to reduce symptoms of intermittent claudication in peripheral artery disease, improving walking distance. It is contraindicated in patients with heart failure of any severity because PDE3 inhibitors have been associated with increased mortality in this population. Headache and palpitations are common side effects reflecting its vasodilatory and cardiac effects.

Masse moléculaire

369,5000 g/mol

LogP

3,10

TPSA

81,90 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Cardiovascular Disease Pain Management Rheumatoid Arthritis Parkinson's Disease Migraine Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Hyperlipidemia Type 2 Diabetes Major Depressive Disorder Breast Cancer Chronic Pain Heart Failure Atrial Fibrillation

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1

InChI

InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

Molecular Formula

C20H27N5O2

HBD / HBA

1 / 5

Liaisons Rotatives

7

Atomes Lourds

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A phosphodiesterase 3 inhibitor that inhibits platelet aggregation and acts as a vasodilator, used to reduce symptoms of intermittent claudication in peripheral artery disease, improving walking distance. It is contraindicated in patients with heart failure of any severity because PDE3 inhibitors have been associated with increased mortality in this population. Headache and palpitations are common side effects reflecting its vasodilatory and cardiac effects.

Yes, Cilostazol is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL799. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 2754. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Cilostazol sur PillFYI

Structure

Données Clés

Formule: C20H27N5O2

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.